SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01848873
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and
plasma homocystein.
Name: Amlodipine
Description: amlodipine 5mg daily
Type: Drug
Group Labels: 1 amolodipine
Name: amlodipine-FA tablet, low dose group
Description: 5mg amlodipine combined with 0.4 mg of folic acid, daily.
Type: Drug
Group Labels: 1 amlodipine-FA tablet, low dose group
Name: amlodipine-FA tablet ,high dose group
Description: amlodipine 5mg and folic acid 0.8mg daily
Type: Drug
Group Labels: 1 amlodipine-FA tablet ,high dose group
Primary Outcomes
Measure: Combined effective rate of blood pressure and plasma homocysteine reduction Time: Blood pressure was examined at baseline and every 2 weeks for a total period of 8 weeks. Blood homocysteine concentrations were measured at baseline and at 4 and 8 weeks of the trial.
Secondary Outcomes
Measure: Blood pressure reduction or plasma homocysteine reduction Time: Blood pressure was examined at baseline and every two weeks for a total period of 8 weeks. Blood homocysteine concentrations was examined at baseline and at 4 and 8 weeks of the trial.
Other Outcomes
Measure: 24-hour ambulatory blood pressure Time: 24-hour ambulatory blood pressure were examined at baseline and at 8 weeks of the trial in 96 participants.
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 C677T
Polymorphism of MTHFR C677T
leads to a reduction in enzyme activity, which may lead to an increased concentration of
plasma homocysteine and lower levels of serum folate, particularly in those with low folate
intake. --- C677T ---
In the present study, we sought to assess: (1) the efficacy and safety of
Amlodipine-folic Acid Tablets in lowering blood pressure and homocystein in patients with
mild to moderate hypertension and hyperhomocysteinemia (hcy≥10μmol/L);(2) if the blood
pressure and homocysteine-lowering efficacy of Amlodipine-folic Acid Tablets can be modified
by individual methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms. --- C677T ---
MTHFR C677T
genotypes were determined for each study subject. --- C677T ---